By Dr Richard Kevin

Journal articles

Bawa Z; Lewis D; Gavin PD; Libinaki R; Joubran L; El-Tamimy M; Taylor G; Meltzer R; Bedoya-Pérez M; Kevin RC; McGregor IS, 2024, 'An open-label feasibility trial of transdermal cannabidiol for hand osteoarthritis', Scientific Reports, 14, http://dx.doi.org/10.1038/s41598-024-62428-x

Sparkes E; Maloney CJ; Markham JW; Dane C; Boyd R; Gilchrist J; Moir M; Gordon R; Luo JL; Pike E; Walker KA; Kassiou M; McGregor IS; Kevin RC; Hibbs DE; Jorgensen WT; Banister SD; Cairns EA; Ametovski A, 2024, 'Structure-Activity Relationships, Deuteration, and Fluorination of Synthetic Cannabinoid Receptor Agonists Related to AKB48, 5F-AKB-48, and AFUBIATA', ACS Chemical Neuroscience, 15, pp. 2160 - 2181, http://dx.doi.org/10.1021/acschemneuro.3c00850

Maguire S; Kesby A; Brownlow R; Hunt GE; Kim M; McAulay C; Grisham JR; McGregor IS; Suraev A; Kevin RC; Russell J, 2024, 'A phase II randomised controlled trial of intranasal oxytocin in anorexia nervosa', Psychoneuroendocrinology, 164, http://dx.doi.org/10.1016/j.psyneuen.2024.107032

Sparkes E; Timmerman A; Markham JW; Boyd R; Gordon R; Walker KA; Kevin RC; Hibbs DE; Banister SD; Cairns EA; Stove C; Ametovski A, 2024, 'Synthesis and Functional Evaluation of Synthetic Cannabinoid Receptor Agonists Related to ADB-HEXINACA', ACS Chemical Neuroscience, 15, pp. 1787 - 1812, http://dx.doi.org/10.1021/acschemneuro.3c00818

Suraev A; McCartney D; Kevin R; Gordon R; Grunstein RR; Hoyos CM; McGregor IS, 2024, 'Detection of Δ⁹-tetrahydrocannabinol (THC) in oral fluid using two point-of-collection testing devices following oral administration of a THC and cannabidiol containing oil', Drug Testing and Analysis, http://dx.doi.org/10.1002/dta.3658

Sparkes E; Markham JW; Boyd R; Udoh M; Gordon R; Zaman H; Walker KA; Dane C; Kevin RC; Santiago MJ; Hibbs DE; Banister SD; Ametovski A; Cairns EA, 2024, 'Synthesis and functional evaluation of proteinogenic amino acid-derived synthetic cannabinoid receptor agonists related to MPP-5F-PICA, MMB-5F-PICA, and MDMB-5F-PICA', RSC Medicinal Chemistry, http://dx.doi.org/10.1039/d3md00758h

Bahceci D; Anderson LL; Kevin RC; Doohan PT; Arnold JC, 2023, 'Hyperthermia-Induced Seizures Enhance Brain Concentrations of the Endocannabinoid-Related Linoleoyl Glycerols in a Scn1a^+/-Mouse Model of Dravet Syndrome', Cannabis and Cannabinoid Research, 8, pp. 495 - 504, http://dx.doi.org/10.1089/can.2022.0145

McCartney D; Kevin RC; Suraev AS; Sahinovic A; Doohan PT; Bedoya-Pérez MA; Grunstein RR; Hoyos CM; McGregor IS, 2023, 'How long does a single oral dose of cannabidiol persist in plasma? Findings from three clinical trials', Drug Testing and Analysis, 15, pp. 334 - 344, http://dx.doi.org/10.1002/dta.3419

Harman T; Udoh M; McElroy DL; Anderson LL; Kevin RC; Banister SD; Ametovski A; Markham J; Bladen C; Doohan PT; Greba Q; Laprairie RB; Snutch TP; McGregor IS; Howland JG; Arnold JC, 2023, 'MEPIRAPIM-derived synthetic cannabinoids inhibit T-type calcium channels with divergent effects on seizures in rodent models of epilepsy', Frontiers in Physiology, 14, http://dx.doi.org/10.3389/fphys.2023.1086243

Mosley PE; Webb L; Suraev A; Hingston L; Turnbull T; Foster K; Ballard E; Gomes L; Mohan A; Sachdev PS; Kevin R; Gordon R; Benson M; McGregor IS, 2023, 'Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome.', NEJM Evid, 2, pp. EVIDoa2300012, http://dx.doi.org/10.1056/EVIDoa2300012

Kevin RC; Cairns EA; Boyd R; Arnold JC; Bowen MT; McGregor IS; Banister SD, 2022, 'Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11', Frontiers in Psychiatry, 13, http://dx.doi.org/10.3389/fpsyt.2022.1048836

Sahinovic A; Irwin C; Doohan PT; Kevin RC; Cox AJ; Lau NS; Desbrow B; Johnson NA; Sabag A; Hislop M; Haber PS; McGregor IS; McCartney D, 2022, 'Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial', Sports Medicine - Open, 8, http://dx.doi.org/10.1186/s40798-022-00417-y

McCartney D; Suraev AS; Doohan PT; Irwin C; Kevin RC; Grunstein RR; Hoyos CM; McGregor IS, 2022, 'Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial', Journal of Psychopharmacology, 36, pp. 1338 - 1349, http://dx.doi.org/10.1177/02698811221095356

Hutten NRPW; Arkell TR; Vinckenbosch F; Schepers J; Kevin RC; Theunissen EL; Kuypers KPC; McGregor IS; Ramaekers JG, 2022, 'Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis', Psychopharmacology, 239, pp. 3731 - 3741, http://dx.doi.org/10.1007/s00213-022-06248-9

Berger M; Li E; Rice S; Davey CG; Ratheesh A; Adams S; Jackson H; Hetrick S; Parker A; Spelman T; Kevin R; McGregor IS; McGorry P; Amminger GP, 2022, 'Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial', Journal of Clinical Psychiatry, 83, http://dx.doi.org/10.4088/JCP.21m14130

Kevin RC; Mirlohi S; Manning JJ; Boyd R; Cairns EA; Ametovski A; Lai F; Luo JL; Jorgensen W; Ellison R; Gerona RR; Hibbs DE; McGregor IS; Glass M; Connor M; Bladen C; Zamponi GW; Banister SD, 2022, 'Putative Synthetic Cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and Their Analogues Are T-Type Calcium Channel (CaV3) Inhibitors', ACS Chemical Neuroscience, 13, pp. 1395 - 1409, http://dx.doi.org/10.1021/acschemneuro.1c00822

Markham J; Sparkes E; Boyd R; Chen S; Manning JJ; Finlay D; Lai F; McGregor E; Maloney CJ; Gerona RR; Connor M; McGregor IS; Hibbs DE; Glass M; Kevin RC; Banister SD, 2022, 'Defining Steric Requirements at CB1and CB2Cannabinoid Receptors Using Synthetic Cannabinoid Receptor Agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and Their Analogues', ACS Chemical Neuroscience, 13, pp. 1281 - 1295, http://dx.doi.org/10.1021/acschemneuro.2c00034

McCartney D; Arkell TR; Irwin C; Kevin RC; McGregor IS, 2022, 'Are blood and oral fluid Δ⁹-tetrahydrocannabinol (THC) and metabolite concentrations related to impairment? A meta-regression analysis', Neuroscience and Biobehavioral Reviews, 134, http://dx.doi.org/10.1016/j.neubiorev.2021.11.004

Arkell TR; Kevin RC; Vinckenbosch F; Lintzeris N; Theunissen E; Ramaekers JG; McGregor IS, 2022, 'Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials', Addiction Biology, 27, http://dx.doi.org/10.1111/adb.13125

Benson MJ; Anderson LL; Low IK; Luo JL; Kevin RC; Zhou C; Mcgregor IS; Arnold JC, 2022, 'Evaluation of the Possible Anticonvulsant Effect of Δ⁹-Tetrahydrocannabinolic Acid in Murine Seizure Models', Cannabis and Cannabinoid Research, 7, pp. 46 - 57, http://dx.doi.org/10.1089/can.2020.0073

Sparkes E; Cairns EA; Kevin RC; Lai F; Grafinger KE; Chen S; Deventer MH; Ellison R; Boyd R; Martin LJ; McGregor IS; Gerona RR; Hibbs DE; Auwärter V; Glass M; Stove C; Banister SD, 2022, 'Structure-activity relationships of valine, tert -leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA', RSC Medicinal Chemistry, 13, pp. 156 - 174, http://dx.doi.org/10.1039/d1md00242b

McCartney D; Kevin RC; Suraev AS; Irwin C; Grunstein RR; Hoyos CM; McGregor IS, 2022, 'Orally administered cannabidiol does not produce false-positive tests for Δ⁹-tetrahydrocannabinol on the Securetec DrugWipe® 5S or Dräger DrugTest® 5000', Drug Testing and Analysis, 14, pp. 137 - 143, http://dx.doi.org/10.1002/dta.3153

Ametovski A; Cairns EA; Grafinger KE; Cannaert A; Deventer MH; Chen S; Wu X; Shepperson CE; Lai F; Ellison R; Gerona R; Blakey K; Kevin R; McGregor IS; Hibbs DE; Glass M; Stove C; Auwärter V; Banister SD, 2021, 'NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity?', ACS Chemical Neuroscience, 12, pp. 4020 - 4036, http://dx.doi.org/10.1021/acschemneuro.1c00348

Anderson LL; Doohan PT; Oldfield L; Kevin RC; Arnold JC; Berger M; Amminger GP; Mcgregor IS, 2021, 'Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People', Journal of Clinical Psychopharmacology, 41, pp. 525 - 533, http://dx.doi.org/10.1097/JCP.0000000000001427

Kevin RC; Vogel R; Doohan P; Berger M; Amminger GP; McGregor IS, 2021, 'A validated method for the simultaneous quantification of cannabidiol, Δ⁹-tetrahydrocannabinol, and their metabolites in human plasma and application to plasma samples from an oral cannabidiol open-label trial', Drug Testing and Analysis, 13, pp. 614 - 627, http://dx.doi.org/10.1002/dta.2947

Arkell TR; Spindle TR; Kevin RC; Vandrey R; McGregor IS, 2021, 'The failings of per se limits to detect cannabis-induced driving impairment: Results from a simulated driving study', Traffic Injury Prevention, 22, pp. 102 - 107, http://dx.doi.org/10.1080/15389588.2020.1851685

Sahinovic A; Irwin C; Kevin RC; Cox AJ; Lau NS; Desbrow B; Johnson NA; Sabag A; Hislop M; Haber PS; McGregor IS; McCartney D, 2021, 'The Effect Of Cannabidiol (CBD) On Exercise Physiology And Bioenergetics: A Randomised Controlled Pilot Trial', Medicine & Science in Sports & Exercise, 53, pp. 280 - 280, http://dx.doi.org/10.1249/01.mss.0000762344.41349.83

Cannaert A; Sparkes E; Pike E; Luo JL; Fang A; Kevin RC; Ellison R; Gerona R; Banister SD; Stove CP, 2020, 'Synthesis and in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA', ACS Chemical Neuroscience, 11, pp. 4434 - 4446, http://dx.doi.org/10.1021/acschemneuro.0c00644

Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG, 2020, 'Effect of Cannabidiol and ?⁹-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial', JAMA - Journal of the American Medical Association, 324, pp. 2177 - 2186, http://dx.doi.org/10.1001/jama.2020.21218

Lintzeris N; Mills L; Dunlop A; Copeland J; Mcgregor I; Bruno R; Kirby A; Montebello M; Hall M; Jefferies M; Kevin R; Bhardwaj A, 2020, 'Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial', Drug and Alcohol Dependence, 215, http://dx.doi.org/10.1016/j.drugalcdep.2020.108220

Assareh N; Gururajan A; Zhou C; Luo JL; Kevin RC; Arnold JC, 2020, 'Cannabidiol disrupts conditioned fear expression and cannabidiolic acid reduces trauma-induced anxiety-related behaviour in mice', Behavioural Pharmacology, 31, pp. 591 - 596, http://dx.doi.org/10.1097/FBP.0000000000000565

Gamage TF; Barrus DG; Kevin RC; Finlay DB; Lefever TW; Patel PR; Grabenauer MA; Glass M; McGregor IS; Wiley JL; Thomas BF, 2020, 'In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018', Pharmacology Biochemistry and Behavior, 193, http://dx.doi.org/10.1016/j.pbb.2020.172918

Arkell TR; Kevin RC; Stuart J; Lintzeris N; Haber PS; Ramaekers JG; McGregor IS, 2019, 'Detection of Δ⁹ THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point-of-collection testing devices', Drug Testing and Analysis, 11, pp. 1486 - 1497, http://dx.doi.org/10.1002/dta.2687

Arkell TR; Lintzeris N; Kevin RC; Ramaekers JG; Vandrey R; Irwin C; Haber PS; McGregor IS, 2019, 'Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition', Psychopharmacology, 236, pp. 2713 - 2724, http://dx.doi.org/10.1007/s00213-019-05246-8

Lintzeris N; Bhardwaj A; Mills L; Dunlop A; Copeland J; McGregor I; Bruno R; Gugusheff J; Phung N; Montebello M; Chan T; Kirby A; Hall M; Jefferies M; Luksza J; Shanahan M; Kevin R; Allsop D, 2019, 'Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial', JAMA Internal Medicine, 179, pp. 1242 - 1253, http://dx.doi.org/10.1001/jamainternmed.2019.1993

Banister SD; Kevin RC; Martin L; Adams A; Macdonald C; Manning JJ; Boyd R; Cunningham M; Stevens MY; McGregor IS; Glass M; Connor M; Gerona RR, 2019, 'The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogs', Drug Testing and Analysis, 11, pp. 976 - 989, http://dx.doi.org/10.1002/dta.2583

Gamage TF; Farquhar CE; McKinnie RJ; Kevin RC; McGregor IS; Trudell ML; Wiley JL; Thomas BF, 2019, 'Synthetic cannabinoid hydroxypentyl metabolites retain efficacy at human cannabinoid receptors', Journal of Pharmacology and Experimental Therapeutics, 368, pp. 414, http://dx.doi.org/10.1124/JPET.118.254425

Kevin RC; Kovach AL; Lefever TW; Gamage TF; Wiley JL; McGregor IS; Thomas BF, 2019, 'Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures', Forensic Toxicology, 37, pp. 17 - 26, http://dx.doi.org/10.1007/s11419-018-0430-0

Kevin RC; Anderson L; McGregor IS; Boyd R; Manning JJ; Glass M; Connor M; Banister SD, 2019, 'CuMyl-4CN-BINACA is an efficacious and potent pro-convulsant synthetic cannabinoid receptor agonist', Frontiers in Pharmacology, 10, http://dx.doi.org/10.3389/fphar.2019.00595

Bedoya-Perez MA; Smith KL; Kevin RC; Luo JL; Crowther MS; Mcgregor IS, 2019, 'Parameters that affect fear responses in rodents and how to use them for management', Frontiers in Ecology and Evolution, 7, http://dx.doi.org/10.3389/fevo.2019.00136

Banister SD; Adams A; Kevin RC; Macdonald C; Glass M; Boyd R; Connor M; McGregor IS; Havel CM; Bright SJ; Vilamala MV; Lladanosa CG; Barratt MJ; Gerona RR, 2019, 'Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA', Drug Testing and Analysis, 11, pp. 279 - 291, http://dx.doi.org/10.1002/dta.2491

Suraev A; Lintzeris N; Stuart J; Kevin RC; Blackburn R; Richards E; Arnold JC; Ireland C; Todd L; Allsop DJ; McGregor IS, 2018, 'Composition and use of cannabis extracts for childhood epilepsy in the australian community', Scientific Reports, 8, http://dx.doi.org/10.1038/s41598-018-28127-0

Suraev A; Lintzeris N; Stuart J; Kevin RC; Blackburn R; Richards E; Arnold JC; Ireland C; Todd L; Allsop DJ; McGregor IS, 2018, 'Erratum to: Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community (Scientific Reports, (2018), 8, 1, (10154), 10.1038/s41598-018-28127-0)', Scientific Reports, 8, http://dx.doi.org/10.1038/s41598-018-30164-8

Banister SD; Olson A; Winchester M; Stuart J; Edington AR; Kevin RC; Longworth M; Herrera M; Connor M; McGregor IS; Gerona RR; Kassiou M, 2018, 'The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs', Drug Testing and Analysis, 10, pp. 1099 - 1109, http://dx.doi.org/10.1002/dta.2362

Gamage TF; Farquhar CE; Lefever TW; Marusich JA; Kevin RC; McGregor IS; Wiley JL; Thomas BF, 2018, 'Molecular and behavioral pharmacological characterization of abused synthetic cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA', Journal of Pharmacology and Experimental Therapeutics, 365, pp. 437 - 446, http://dx.doi.org/10.1124/jpet.117.246983

Kevin RC; Lefever TW; Snyder RW; Patel PR; Fennell TR; Wiley JL; McGregor IS; Thomas BF, 2018, 'Erratum to: In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA (Forensic Toxicol, (2017), 35, (333–347), 10.1007/s11419-017-0361-1)', Forensic Toxicology, 36, pp. 229, http://dx.doi.org/10.1007/s11419-017-0380-y

Kevin RC; Lefever TW; Snyder RW; Patel PR; Gamage TF; Fennell TR; Wiley JL; McGregor IS; Thomas BF, 2018, 'Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18', Drug Testing and Analysis, 10, pp. 137 - 147, http://dx.doi.org/10.1002/dta.2262

Longworth M; Banister SD; Boyd R; Kevin RC; Connor M; McGregor IS; Kassiou M, 2017, 'Pharmacology of Cumyl-Carboxamide Synthetic Cannabinoid New Psychoactive Substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and Their Analogues', ACS Chemical Neuroscience, 8, pp. 2159 - 2167, http://dx.doi.org/10.1021/acschemneuro.7b00267

Kevin RC; Lefever TW; Snyder RW; Patel PR; Fennell TR; Wiley JL; McGregor IS; Thomas BF, 2017, 'In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA', Forensic Toxicology, 35, pp. 333 - 347, http://dx.doi.org/10.1007/s11419-017-0361-1

Kevin RC; Wood KE; Stuart J; Mitchell AJ; Moir M; Banister SD; Kassiou M; McGregor IS, 2017, 'Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA', Journal of Psychopharmacology, 31, pp. 757 - 769, http://dx.doi.org/10.1177/0269881116684336

Back to profile page